Drug profile · INN
rabeprazole sodium
RABEPRAZOLE SODIUM
rabeprazole sodium (RABEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — rabeprazole sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
rabeprazole sodium (RABEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium-transporting ATPase inhibitor
Primary target: Potassium-transporting ATPase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rabeprazole sodium?
rabeprazole sodium (RABEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rabeprazole sodium?
RABEPRAZOLE SODIUM is a marketed brand name for rabeprazole sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rabeprazole sodium?
rabeprazole sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.